Tests blood-guided treatment in people with colon cancer after surgery

Trial details

Who runs it

IFOM ETS - The AIRC Institute of Molecular Oncology

Trial code

NCT06490536EU 2023-509851-15-00

Record updated

29 August 2025

Original description

Background \& Rationale:Read full original descriptionShow less

A Precision Medicine Trial Leveraging Blood-Based Tumor Genomics to Optimize Treatment in Operable Stage III and High-Risk Stage II Colon Cancer Patients

Background \& Rationale:

Colon cancer is a leading cause of cancer deaths, with a high recurrence rate in stage II high-risk and stage III patients due to undetectable micro-metastases. Liquid biopsy (LB) detects residual cancer DNA post-surgery and monitors treatment response.

Primary Objective:

Show that therapy based on tumor genetics and LB improves outcomes and quality of life for high-risk stage II and stage III colon cancer patients compared to conventional therapy.

Secondary Objectives:

Compare recurrence times. Evaluate side effects and quality of life. Assess cost differences. Validate LB accuracy.

Study Design: Patients are randomized into standard or personalized treatment groups based on LB results.

For positive LB results:

Randomized to standard or customized therapy. Monitor treatment response with LB.

For negative LB results:

Randomized to standard chemotherapy or follow-ups, starting treatment if a positive result appears.

Treatments:

Standard Chemotherapy:

CAPOX (capecitabine and oxaliplatin) FOLFOX (folinic acid, fluorouracil, and oxaliplatin)

Personalized Treatments:

Customized chemotherapy with CAPOX. Immunotherapy with nivolumab and ipilimumab. Targeted therapy with trastuzumab and pertuzumab. FOLFOX with anti-EGFR (epidermal growth factor receptor) therapy (panitumumab).

Population: 700 patients with operable stage III and high-risk stage II colon cancer.

Inclusion Criteria:

Aged 18 or older. Confirmed diagnosis. Tumor tissue sample available.

Exclusion Criteria:

History of other tumors within five years. Metastatic disease or recent experimental study participation. Major cardiovascular diseases, intestinal obstruction, autoimmune diseases, neuropathy, HIV (Human Immunodeficiency Virus), active TB (Tuberculosis), or hepatitis B/C infection.

Medical conditions contraindicating treatment. Prior neoadjuvant treatment administered before surgery.

Endpoints:

Primary:

Evaluate disease recurrence after two years.

Secondary:

Assess disease recurrence and overall survival at 3 and 5 years. Measure treatment safety and tolerability. Validate LB accuracy. Monitor quality of life using questionnaires.

The study will last 5 years and be conducted in 25-30 hospitals across Italy, Spain, and Germany.

Inclusion: SAGITTARIUS trial written informed consent; Age ≥ 18 years; Histologically confirmed diagnosis of operable stage III and High-Risk stage II CC located at least 12 cm from the anal verge by endoscopy and above the peritoneal reflection at surgery; Availability of the original FFPE tumor tissue; ECOG performance status 0-1; Normal organ functions (as defined in section 9.3); Women with childbearing potential (WOCBP) should complete a pregnancy test and be willing to use highly effective contraceptive methods.

Exclusion: Current or recent treatment with another investigational drug or participation in another investigational study; Prior neoadjuvant treatment administered before surgery; Macroscopic or microscopic evidence of residual tumor (R1 or R2 resections). Patients should never have had any evidence of metastatic disease (including presence of tumor cells in the peritoneal lavage); Clinically relevant cardiovascular disease; Acute or subacute intestinal occlusion or history of inflammatory bowel disease or any other autoimmune disease; Pre-existing neuropathy > grade 1. Known grade 3 or 4 allergic reaction to any of the components of the treatment; Has a known history of Human Immunodeficiency Virus (HIV); Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus infection; Has a known history of active TB (Bacillus Tuberculosis); Has a medical condition that contraindicate the use of the investigational medicinal product (IMP) according to product indications; History of another neoplastic disease, unless in remission for ≥ 5 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded; Patient unable to comply with the study protocol owing to psychological, social or geographical reasons; Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study; Inadequate contraception (male or female patients) if of childbearing or procreational potential.

ClinicalTrials.gov NCT06490536 · EU CTIS 2023-509851-15-00